RxNorm 2268044

Zirabev 100 MG in 4 ML Injection

RxNorm Semantic Concepts

RxNorm semantic concepts for the RxCUI 2268044 unique identifier include: Zirabev 100 MG in 4 ML Injection (11812432), 4 ML bevacizumab-bvzr 25 MG/ML Injection [Zirabev] (11812425), Zirabev 25 MG/ML per 4 ML Injection (11812430) and Zirabev 100 MG per 4 ML Injection (11812431).

RxNorm Atom ID: 11812432 - Prescribable Name
Zirabev 100 MG in 4 ML Injection

RXCUI:
2268044 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
11812432 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
Zirabev 100 MG in 4 ML Injection - Description of concept identifier
Term Type (TTY):
PSN - Term type in source with name and description
Term Type Name:
Prescribable Name - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept. - Description of term type in source
Code:
2268044 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 11812425 - Semantic Branded Drug
4 ML bevacizumab-bvzr 25 MG/ML Injection [Zirabev]

RXCUI:
2268044 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
11812425 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
4 ML bevacizumab-bvzr 25 MG/ML Injection [Zirabev] - Description of concept identifier
Term Type (TTY):
SBD - Term type in source with name and description
Term Type Name:
Semantic Branded Drug - Name of term type in source
Term Type Description:
Ingredient + Strength + Dose Form + Brand Name - Description of term type in source
Code:
2268044 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom 11812425 Attributes

PropertyValueExplanation
RXN AI{2268038} 253337RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM{2268038} 253337RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH25 MG/ML (expressed as bevacizumab-bvzr)Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM{2268038} AISource of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUGUSDrug available for use in Humans
RXN QUANTITY4 MLNormal Form quantity factor

RxNorm Atom ID: 11812430 - Synonym
Zirabev 25 MG/ML per 4 ML Injection

RXCUI:
2268044 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
11812430 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
Zirabev 25 MG/ML per 4 ML Injection - Description of concept identifier
Term Type (TTY):
SY - Term type in source with name and description
Term Type Name:
Synonym - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity. - Description of term type in source
Code:
2268044 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

RxNorm Atom ID: 11812431 - Synonym
Zirabev 100 MG per 4 ML Injection

RXCUI:
2268044 - RxNorm Unique Identifier for a concept (Concept ID)
LAT:
ENG - Language of the Term
RXAUI:
11812431 - Unique identifier for the atom (RxNorm Atom ID)
Is Prescribable?
YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
Concept Description:
Zirabev 100 MG per 4 ML Injection - Description of concept identifier
Term Type (TTY):
SY - Term type in source with name and description
Term Type Name:
Synonym - Name of term type in source
Term Type Description:
Synonym of another TTY, given for clarity. - Description of term type in source
Code:
2268044 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
Suppress Flag:
N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility.
CVF:
4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
Source:
RXNORM - Concept source abbreviation
Source Name:
RxNorm Vocabulary - The official name for a source
Source Version:
20AA_240304F - The source version
Source Date:
March 04, 2024 - RxNorm data last updated
Source License Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information
Source Content Contact:
RxNorm Customer Service

U.S. National Library of Medicine
8600 Rockville Pike

Bethesda
MD
United States
20894
(888) FIND-NLM

[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information
Source Short Name:
RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server

* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Patient Education

Bevacizumab Injection


Bevacizumab injection products are used in combination with other chemotherapy medications to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body; in combination with other chemotherapy medications to treat certain types of lung cancer that has spread to nearby tissues or other parts of the body, that cannot be removed by surgery, or have returned after treatment with other chemotherapy medications; to treat glioblastoma (a certain type of cancerous brain tumor) that has not improved or has come back after treatment with other medications; in combination with interferon alfa to treat renal cell cancer (RCC, a type of cancer that begins in the kidney) that has spread to other parts of the body; in combination with other chemotherapy medications to treat cervical cancer (cancer that begins in the opening of the uterus [womb]) that has not improved or has come back after treatment with other medications or has spread to other parts of the body; in combination with other chemotherapy medications to treat certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer that has not improved or has come back after treatment with other medications; and in combination with atezolizumab to treat hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery in people who have not previously not received chemotherapy. Bevacizumab injection products are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.